Abstract:
:In this study, we report that the related adhesion focal tyrosine kinase RAFTK, is an upstream kinase in beta1 integrin mediated activation of Akt. Stimulation through beta1 integrins by fibronectin reversed apoptosis induced by adriamycin. Inhibitors of phosphatidylinositol 3-kinase (PI3 kinase)/Akt (LY 294002), tyrosine kinases (Herbimycin-A) and the cytotoxic agent adriamycin induced apoptosis of REH cells. beta1 integrin ligation induced activation of Akt, and tyrosine phosphorylation of RAFTK and FAK, but not SYK in REH cells. This suggested that RAFTK and FAK activation might be linked to Akt activation. Evidence that RAFTK is a modulator of Akt came from phorbol myristic acetate (PMA) stimulation. RAFTK and Akt were activated but FAK was not. Using fibroblasts from FAK -/- mice, which express high levels of RAFTK, fibronectin plating enhanced Akt activation. Pretreatment of REH cells with a P13 kinase/Akt inhibitor LY 294002 did not inhibit RAFTK tyrosine phosphorylation showing that RAFTK is upstream of P13k/Akt. Further evidence for a link between RAFTK tyrosine phosphorylation and Akt activation was the observation that the p85 subunit of P13 kinase associated with RAFTK following integrin ligation in REH cells. These results suggest that RAFTK plays an anti-apoptotic role through the activation of Akt.
journal_name
Leuk Lymphomajournal_title
Leukemia & lymphomaauthors
Sarkar S,Svoboda M,de Beaumont R,Freedman ASdoi
10.1080/1042819021000003009keywords:
subject
Has Abstractpub_date
2002-08-01 00:00:00pages
1663-71issue
8eissn
1042-8194issn
1029-2403journal_volume
43pub_type
杂志文章abstract::Reprimo (RPRM) is a novel tumor suppressor. However, the expression and molecular function of RPRM in pediatric acute myeloid leukemia (AML) is still unknown. We observed hypermethylation of the RPRM promoter in 8/11 leukemia cell lines and in 44.8% (47/105) of pediatric AML samples compared with 6.7% (2/30) of contro...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2015.1011157
更新日期:2015-01-01 00:00:00
abstract::Fludarabine (FLUDA) based chemotherapy has shown promise in both initial and salvage treatment of low-grade non Hodgkin's lymphomas (LG-NHL). Recently, more aggressive therapies followed by autologous hemopoietic progenitor cell rescue, have also been successfully employed in these patients. However, this procedure, d...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190009057639
更新日期:2000-03-01 00:00:00
abstract::We describe a patient with extranodal (pulmonary) marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) who was refractory to treatment with cytotoxic chemotherapy. After a single four-week course of rituximab she had significant regression of pulmonary lesions and remains progression free 19 month...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190500137890
更新日期:2005-09-01 00:00:00
abstract::We attempted to analyze whether the use of high-dose cyclophosphamide (CTX 7g/m2, group A) plus hematopoietic growth factor (G-CSF) or G-CSF alone (10 microg/Kg, group B) as a mobilizing regimen, could result in harvesting different numbers of CD34+ cells, committed progenitors and CD34+ cells subsets. The number of C...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190009065829
更新日期:2000-10-01 00:00:00
abstract::A clinical case of patient with a simultaneous gastrointestinal stromal tumors (GIST) and MALT lymphoma in relapse is presented. Simultaneous treatment with imatinib mesylate and rituximab was given, yielded response for both tumors and was well tolerated. ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190412331272712
更新日期:2004-11-01 00:00:00
abstract::Angiogenesis is a necessary step in solid tumor progression (growth, invasion and metastasis) with which it correlates and is indicative of an unfavourable prognosis. We observed bone marrow angiogenesis in patients with active multiple myeloma (MM), though not in patients with non-active MM nor with monoclonal gammop...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199509054750
更新日期:1995-12-01 00:00:00
abstract::The mammalian target of rapamycin (mTOR) pathway is a major therapeutic target in the treatment of hematological malignancies, as it controls cellular events of high importance for regulation of mRNA translation and protein production. Rapalogs, or first-generation mTOR inhibitors, have produced only modest clinical b...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2015.1026816
更新日期:2015-01-01 00:00:00
abstract::Several techniques developed in recent years provide us with the capability to detect sub-microscopic leukemia during remission. Quantitative polymerase chain reaction (PCR) is thus far the most sensitive assay that is applicable in most patients with acute lymphoblastic leukemia (ALL) of childhood. However, false-pos...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199909093724
更新日期:1999-03-01 00:00:00
abstract::In this report, we present a patient with chronic myeloid leukemia (CML) in blastic phase who had two consecutive episodes of spontaneous regression back to chronic phase without chemotherapy. Although, spontaneous remission (SR) is well documented in acute leukemia, SR in CML blastic phase is extremely rare and to th...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199809068579
更新日期:1998-04-01 00:00:00
abstract::To distinguish the similarities or differences between T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), we retrospectively analyzed the clinical, immunophenotypic, cytogenetic, and molecular characteristics in 37 children diagnosed between December 1990 and December 2003. Compara...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190701509772
更新日期:2007-09-01 00:00:00
abstract::Venocclusive disease of the liver (VOD) is one of the most common and serious complications following stem cell transplantation. High-dose chemotherapy or chemoradiotherapy injures the structures of Zone 3 of the liver acinus and produces the clinical syndrome of hepatomegaly or right upper quadrant pain, jaundice, an...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199809059219
更新日期:1998-10-01 00:00:00
abstract::The outcomes of acute promyelocytic leukemia (APL) in pregnancy are largely unknown. The MEDLINE database was systematically searched to obtain 43 articles with 71 patients with new-onset APL during pregnancy. Induction therapy included various regimens of all-trans retinoic acid (ATRA), cytarabine, and anthracycline ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,meta分析
doi:10.3109/10428194.2015.1065977
更新日期:2016-01-01 00:00:00
abstract::Primary gynecologic myeloid sarcomas are rare, and their diagnosis is often difficult. Differential diagnosis includes lymphomas and carcinomas of the gynecologic tract. We report the clinical, morphological, immunohistochemical and cytogenetic features of two cases of chloromas of the female genital tract, which prog...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/1042819021000016096
更新日期:2002-11-01 00:00:00
abstract::Whether long non-coding RNA (lncRNA) single-nucleotide polymorphisms (SNPs) affect prognosis of acute myeloid leukemia (AML) remains unknown. To search the association between lncRNA SNPs and AML outcomes, thirty tagSNPs in five lncRNAs were genotyped in 313 AML patients. Survival analysis indicated that GAS5 rs558296...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2016.1266626
更新日期:2017-08-01 00:00:00
abstract::In acute myeloid leukemia (AML), cytogenetics predicts treatment outcome for the favorable and poor subgroups but not for the intermediate subgroup. Polymorphisms within the nucleotide excision repair (NER) pathway may lead to interindividual differences in DNA repair capacity, influencing outcome. We studied the role...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428190903582804
更新日期:2010-04-01 00:00:00
abstract::The prednisone, etoposide, procarbazine and cyclophosphamide (PEP-C) oral combination chemotherapy regimen (prednisone 20 mg, cyclophosphamide 50 mg, etoposide 50 mg, and procarbazine 50 mg with an oral anti-emetic) was employed at our center to treat 22 patients with heavily pretreated, recurrent mantle cell lymphoma...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190701837330
更新日期:2008-03-01 00:00:00
abstract::B-cell chronic lymphocytic leukemia (CLL) is a clonal B cell malignancy of morphologically mature, functionally immature B cells. B-cell CLL cells are known to be resistant to killing by anticancer and other agents. This resistance is associated with alterations in apoptosis and cell cycle regulated genes. In our earl...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/1042819021000006411
更新日期:2002-09-01 00:00:00
abstract::This study reports the clinical, haematological and immunophenotypic features of a series of 25 patients with clonal expansions of large granular lymphocytes (LGL)/NK-associated (NKa) cells. These showed a male predominance (16:9) with a median age of 67 (range 38-91) years; four had a documented history of rheumatoid...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199509056836
更新日期:1995-04-01 00:00:00
abstract::Human herpesvirus 8 (HHV-8 or Kaposi's sarcoma herpesvirus) is a gamma herpesvirus that is most likely the etiologic agent of both Kaposi's sarcoma and primary effusion lymphoma (PEL), a rare HIV-associated lymphoma. The role of HHV-8 in post-transplant lymphoma is less well characterized. We demonstrate that HHV-8 is...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190290012173
更新日期:2002-03-01 00:00:00
abstract::Hairy cell leukemia (HCL), a rare haematological disorder of B-cell origin, mainly presents with bone marrow infiltration, haematopoietic insufficiency, and splenomegaly. In some cases, osteolytic lesions can be observed. Many of these clinical features, especially haematopoietic insufficiency and osteolytic lesions a...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199509056850
更新日期:1995-05-01 00:00:00
abstract::Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificit...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.1080/10428190801896103
更新日期:2008-04-01 00:00:00
abstract::Morbidity, mortality and discomfort related to gastrectomy has led some investigators to treat patients with stage I-II primary gastric high-grade lymphoma (PGL) with a conservative strategy. Here we report a retrospective series of 21 patients with PGL treated with primary chemotherapy alone or followed by radiation ...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199909058457
更新日期:1999-05-01 00:00:00
abstract::We treated 15 patients with therapy related acute nonlymphocytic leukemia (tANLL) or therapy related myelodysplastic syndrome (tMDS) who had no rearrangements of chromosomes 5 and/or 7 or complex cytogenetic rearrangements by intensive chemotherapy. The median age was 43 years. Seven patients had one of the "specific"...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428199109068114
更新日期:1991-01-01 00:00:00
abstract::We have recently shown that the lysosomotropic amine, chloroquine, can inhibit the development of graft-versus-host disease (GVHD) secondary to minor histocompatibility (MiHC) differences in mice. In addition, we have shown that both chloroquine and hydroxychloroquine can inhibit T cell responses in vitro to minor and...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428199709039008
更新日期:1997-01-01 00:00:00
abstract::Due to Cytochrome P450 3A (CYP3A) metabolism, clinical trials of ibrutinib-treated chronic lymphocytic leukemia (CLL) patients prohibited concurrent medications metabolized by CYP3A. We evaluated concomitant medication use in 118 ibrutinib-treated CLL patients outside the context of clinical trials. Seventy-five (64%)...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428194.2016.1251592
更新日期:2017-06-01 00:00:00
abstract::Few studies have examined the association between methylenetetrahydrofolate reductase (MTHFR) SNPs, epigenetic changes, and multiple myeloma (MM). We wished to determine genotype distributions for MTHFR 1298AC SNP in cases of MM and healthy controls and to examine whether there is any correlation between the methylati...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2010.528095
更新日期:2010-12-01 00:00:00
abstract::Central venous access devices (CVADs) are used for intravenous therapy in patients with hematological malignancies. There are limited data comparing catheter outcomes in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. A retrospective review comparing the incidence of early and late CVAD-a...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.3109/10428194.2012.742520
更新日期:2013-06-01 00:00:00
abstract::The European Society for Blood and Marrow Transplantation Chronic Malignancies Working Party held a preceptorship meeting in Turin, Italy on 25-26 September 2014, to discuss the role of stem cell transplantation (SCT) in the treatment of multiple myeloma and other plasma cell disorders. Scientists and clinicians worki...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章,评审
doi:10.3109/10428194.2015.1131278
更新日期:2016-01-01 00:00:00
abstract::Despite progress in AML therapy, most patients eventually relapse, even the ones with normal or favorable karyotype. Since survival is poor once relapse occurs, new genetic tools above karyotype at diagnosis are needed to predict leukemia free survival. Recently, Flt3/ITD has been reported as an independent marker for...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/1042819031000151851
更新日期:2004-01-01 00:00:00
abstract::The fusion toxin DT388IL3 composed of the catalytic and translocation domains of diphtheria toxin (DT388) linked to interleukin-3 (IL3) was administered to 6 cynomolgus monkeys which possessed cross-reactive IL3 receptors. Groups of 2 animals (1 male and 1 female) received up to 6 every other day slow intravenous infu...
journal_title:Leukemia & lymphoma
pub_type: 杂志文章
doi:10.1080/10428190410001663572
更新日期:2004-08-01 00:00:00